A Randomized, Double-Blind, Active-Control, Parallel-Group, 90-Day Safety Study of CG5503 Immediate Release (IR) or Oxycodone IR in Subjects With Chronic Pain From Low Back Pain or Osteoarthritis of the Hip or Knee.

Trial Profile

A Randomized, Double-Blind, Active-Control, Parallel-Group, 90-Day Safety Study of CG5503 Immediate Release (IR) or Oxycodone IR in Subjects With Chronic Pain From Low Back Pain or Osteoarthritis of the Hip or Knee.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 May 2010

At a glance

  • Drugs Oxycodone; Tapentadol
  • Indications Back pain; Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 07 May 2010 Post-hoc analysis data to be presented as a poster at the 2010 American Pain Society Annual Meeting.
    • 22 Sep 2009 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.
    • 17 Aug 2008 Secondary endpoint 'Pain intensity' has been met, with no significant differences between tapentadol and oxycodone.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top